BOCA RATON, Fla., Feb. 7 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI) announced today that Thomas H. McLain,
chairman, chief executive officer and president, and Henrik Rasmussen,
M.D., Ph.D., senior vice president, clinical, medical and regulatory
affairs, will participate in the BIO CEO and Investor Conference 2007 on
Monday, February 12, 2007, at the Waldorf Astoria Hotel, 301 Park Avenue,
New York, New York. Mr. McLain will present a company overview at 11:00 am
EST (Jade Room) and Dr. Rasmussen will participate in a panel discussion at
9:30 am EST (West Foyer) on Hepatitis C Virus (HCV): How Companies Are
Ramping Up R&D.
Mr. McLain's presentation will be webcast live at:
http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=NABI&item_id=14667
99
The webcast will be available through March 12, 2007.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in
powering the immune system to develop and market products that fight
serious medical conditions. The company has two products on the market
today: Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM)
(allopurinol sodium) for Injection. Nabi Biopharmaceuticals is focused on
developing products that address unmet medical needs and offer commercial
opportunities in our core business areas: Hepatitis and transplant,
Gram-positive bacterial infections and nicotine addiction. For a complete
list of pipeline products, please go to:
http://www.nabi.com/pipeline/index.php. The company is headquartered in
Boca Raton, Florida. For additional information about Nabi
Biopharmaceuticals, please visit our website at http://www.nabi.com.
SOURCE Nabi Biopharmaceuticals
 back to top
Related links:
http://www.nabi.com/
CONTACT:
Tom Rathjen, Vice President, Investor
Relations, of Nabi Biopharmaceuticals, +1-561-989-5800
|
